Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination GAITHERSBURG, Md. , April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that its partner, Takeda,  received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for its Nuvaxovid™ Intramuscular Injection (Nuvaxovid), Novavax' novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

Johnson & Johnson

Moderna

Coronavirus vaccine stocks worth knowing as Covid-19 remains a global public health emergency.

Best Stocks To Invest In Now? 3 Coronavirus Vaccine Stocks To Know

BioNTech SE

Each vaccine stock is moving lower for a different reason.

Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today

Novavax continues to await FDA news about its Covid-19 vaccine, but that's not everything that drives the price of NVAX stock. The post What Volatility in Novavax Means for Investors appeared first on InvestorPlace.

What Volatility in Novavax Means for Investors

New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine GAITHERSBURG, Md. , April 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022.

Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

The delay in FDA approval is making the opportunity smaller for Novavax, but the opportunity still remains. NVAX stock is a hold.

The Longer the Wait, The Smaller the Opportunity for Novavax

Novavax made its vaccine in the traditional way and with an adjuvant to let it cover more people. But people still seem to prefer mRNA vaccines.

Novavax: The Party's Over

Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.

Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland

NVAX stock is likely to remain depressed as the market for covid-19 vaccine shrinks. Combination vaccines can be a positive catalyst.

Will Novavax Stock Continue to Trend Lower?

Yet another regulator green-lights the company's coronavirus jab.

Why Novavax Crushed the Market Today

Novavax's Covid-19 vaccine Nuvaxovid just got approved for in Switzerland. NVAX stock is up on news.

Novavax Stock Up on Swiss Approval of Nuvaxovid

Swissmedic, the Swiss Agency for Therapeutic Products, has granted conditional marketing authorization for Novavax Inc's (NASDAQ: NVAX) Nuvaxovid COVID-19 Vaccine for individuals 18 years of age and older.  The vaccine, also known as NVX-CoV2373, is the first protein-.

Novavax's COVID-19 Vaccine Approved In Switzerland

- Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Switzerland GAITHERSBURG, Md. , April 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Novavax lost nearly one-fifth of its value in the last week and risks further selling pressure, despite offering an mRNA alternative. The post Novavax Stock Is Slumping: Why Buy the Dip?

Novavax Stock Is Slumping: Why Buy the Dip?

NVAX stock isn't a darling on Wall Street right now, but a rally could be just around the corner as Novavax pursues its global ambitions. The post Novavax Stock Is Tanking Despite New Covid-19 Vaccine Authorization appeared first on InvestorPlace.

Novavax Stock Is Tanking Despite New Covid-19 Vaccine Authorization

Pfizer

As COVID-19 becomes endemic, what will the market look like for therapies and vaccines?

These COVID Stocks Will Be Incredibly Profitable

Vir Biotechnology

The market is so pessimistic about anything COVID-related that everything has gotten super cheap.

3 Pharmaceutical Stocks With Awesome Futures

With FDA authorization likely on the horizon, Novavax is positioned for even greater success.

This Cheap Stock Is Making Billions in Biotech

The company's coronavirus vaccine is authorized for use in another Asian country.

Why Novavax Stock Topped the Market on Friday

The company is still waiting for the FDA to give Emergency Use Authorization for its COVID-19 vaccine.

Why Novavax Stock Dropped 23.6% This Week

GAITHERSBURG, Md., and PUNE, India , April 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand

The major covid-19 vaccine makers are all down, anticipating bad-for-business news from the FDA. However, NVAX stock has the most to lose.

Vaccine Makers Down on FDA Meeting, Novavax Most at Risk

Researchers compared Novavax's vaccine to three others on the market, offering a thorough glimpse of protection from boosters. The post Dear Biotech Investors: Novavax's Comparable Vaccine Matters appeared first on InvestorPlace.

Dear Biotech Investors: Novavax's Comparable Vaccine Matters

NVAX stock could slide even further as research & development requirements stack up against its balance sheet's capacity. The post Is NVAX Stock a Buy at 52-Week Low?

Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection

NVAX stock is still falling. Get paid for your patience to be a buyer at lower levels by selling expensive puts.

News for Novavax Stock (NVAX)